There have been a lot of shifts lately behind the reasons people start new biotech companies. Academic and nonprofit sources of biomedical...

Drug products are evolving long tails and they are going to carry costs for firms well into the future. Drug safety commitments in the US an...

Alkermes said today that it expects Eli Lilly to discontinue the companies' AIR Insulin collaboration: Lilly has informed Alkermes that ...

Deep breath in. Deep breath out. Nektar execs, have you found your quiet place, yet? It's been a stressful few months for Nektar employe...

The dismal failure of Pfizer/Nektar’s Exubera loudly called into question whether inhaled mealtime insulin was commercially viable at all. ...

Break up to make up, that's all we do First you love me then you hate me, that's a game for fools. Has Carl Icahn soured on BiogenId...

Most of the releases we receive are from dedicated health care PR pros. If the topics aren't right up our alley, then they tend to be at...

( With apologies to Joseph Heller. ) … We will courtmartial you if you turn our deal down, even though it would raise a lot of questions and...

Pfizer CEO Jeff Kindler must have been gritting his teeth as he read out loud the costs of the now-terminated Exubera inhaled insulin produc...

Pfizer launched its first TV campaign for Exubera this past week in an attempt to breathe a little life into the stalled inhaled insulin br...

Pfizer isn't the only company having problems with an alternative delivery form of insulin . Emisphere Technologies has been working on ...

It's just what Pfizer didn't need: another expensive failure. Less than six months after the much-vaunted Lipitor -replacement torce...

Many analysts have questioned the potential of Pfizer’s inhaled insulin, Exubera . Nonetheless, it was more than surprising to see the comme...